| Filed On | Filing |
|---|---|
| 13 Nov 2026 | 10-Q |
| 12 Nov 2026 | EFFECT |
| 12 Nov 2026 | 424B3 |
| 10 Nov 2026 | S-4/A |
| 10 Nov 2026 | 425 |
| 09 Nov 2026 |
8-K: Regulation FD Disclosure
Werewolf Therapeutics’ Clinical Data for WTX-124 and WTX-330 Presented at the Society for Immunotherapy of Cancer’s (SITC) 2026 Annual Meeting |
| 26 Oct 2026 | REGISTRATION OF SECURITIES ISSUED IN BUSINESS COMBINATION TRANSACTIONS |
| 22 Sep 2026 | S-4 |
| 21 Sep 2026 | SCHEDULE 13G |
| 21 Aug 2026 | 425 |
| 21 Aug 2026 |
8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +1 more
THIS AGREEMENT AND PLAN OF MERGER (this “Agreement”) is made and entered into as of August 21, 2026, by and among AMBROS THERAPEUTICS, INC., a Delaware corporation (“Ambros”), WEREWOLF THERAPEUTICS, INC., a Delaware corporation (“Werewol... |
| 20 Aug 2026 |
8-K: Entry into a Material Definitive Agreement
On August 14, 2026 (the “Closing”), Werewolf Therapeutics, Inc. (the “Company”) entered into an asset purchase agreement (the “Purchase Agreement”) with EMD Serono Research & Development Institute Inc. (“EMD”), pursuant to which, and sub... |
| 31 Jul 2026 | 10-Q |
| 31 Jul 2026 |
8-K: Results of Operations and Financial Condition
Watertown, Mass., July 31, 2026 (GLOBE NEWSWIRE) – Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engin... |
| 08 Jul 2026 |
Form 4: Evnin Luke, Director
Sold 35,770 shares ($11.4K) · Sold 107,429 shares ($33.3K) |
| 06 Jul 2026 | 144 |
| 06 Jul 2026 | 144 |
| 06 Jul 2026 | 144 |
| 06 Jul 2026 | 144 |
| 06 Jul 2026 | 144 |
Loading...